145
Participants
Start Date
February 28, 2009
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
GAD-Alum
Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
GAD-Alum and Aluminum hydroxide
Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
Aluminum hydroxide
Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
Columbia University, New York
Childrens Hospital of Pittsburgh, Pittsburgh
University of Miami/ Miller School of Medicine, Miami
Indiana University School of Medicine, Indianapolis
University of Minnesota, Minneapolis
Barbara Davis Center for Childhood Diabetes/University of Colorado Health Sciences Center, Aurora
Childrens Hospital of Los Angeles, Los Angeles
University of California-San Francisco, San Francisco
Stanford University, Palo Alto
Benaroya Research Institute, Seattle
Yale University School of Medicine, New Haven
University of Florida, Gainesville
Joslin Diabetes Center, Boston
University of Texas/Southwestern Medical School, Dallas
Hospital for Sick Children, Toronto
Collaborators (1)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
National Center for Research Resources (NCRR)
NIH
American Diabetes Association
OTHER
Juvenile Diabetes Research Foundation
OTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH